# To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

> **NCT06646354** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Hyundai Pharm** · enrollment: 125 (estimated)

## Conditions studied

- Hypertension
- Primary Hypercholesterolaemia

## Interventions

- **DRUG:** Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
- **DRUG:** Candesartan/Amlodipine
- **DRUG:** Candesartan/Rosuvastatin/Ezetimibe

## Key facts

- **NCT ID:** NCT06646354
- **Lead sponsor:** Hyundai Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-22
- **Primary completion:** 2025-05-19
- **Final completion:** 2028-12-31
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06646354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06646354, "To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06646354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*